What is ProteinQure?
ProteinQure operates at the forefront of biotechnology, focusing on the creation of exotic peptides designed for broad therapeutic applications. The company's core technology, ProteinStudio, employs sophisticated molecular simulations and artificial intelligence to engineer peptides that enable tissue-specific drug delivery. This precision approach aims to enhance therapeutic efficacy while substantially reducing adverse side effects. ProteinQure's platform is validated through collaborations with leading pharmaceutical entities, positioning it as a key player in the advancement of precision medicine and improved patient treatment outcomes.
How much funding has ProteinQure raised?
ProteinQure has raised a total of $15M across 2 funding rounds:
Angel/Seed
$4M
Series A
$11M
Angel/Seed (2019): $4M with participation from Global Founders Capital, Felicis Ventures, Tom Williams, 8VC, iNovia, and Golden Ventures
Series A (2025): $11M, investors not publicly disclosed
Key Investors in ProteinQure
Global Founders Capital
Global Founders Capital is a global early-stage investor that empowers gifted entrepreneurs by backing them from pre-seed to IPO. With a track record of supporting over five hundred entrepreneurs worldwide, including notable companies like Facebook and LinkedIn, GFC focuses on category-defining ventures.
Felicis Ventures
Feliciss is a Menlo Parkbased venture capital firm that raises multistage funds to invest in early and growthstage technology companies across sectors such as SaaS, AI, fintech, and consumer, typically leading seed and Series A rounds and supporting founders through scaleup and exit.
8VC
8 | Partners is a company that operates in the Government industry. It employs 20to49 people and has 1Mto5M of revenue. The company is headquartered in Saint Vincent and the Grenadines.
What's next for ProteinQure?
With the recent influx of major strategic investment, ProteinQure is well-positioned to further scale its operations and advance its pipeline of novel therapeutic peptides. The company's focus on leveraging advanced computational tools and AI for drug discovery aligns with the growing demand for precision medicine solutions. Future developments are likely to involve expanding its partnership network with Tier 1 pharma companies, further validating its platform, and potentially moving towards clinical trials for its most promising peptide candidates. This strategic financing will be critical in navigating the complex drug development pathway and achieving its goal of transforming patient care.
See full ProteinQure company page
